Camrelizumab
- Generic Name
- Camrelizumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1798286-48-2
- Unique Ingredient Identifier
- 73096E137E
- Background
Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).
- Indication
⑴用于至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤患者的治疗。
⑵用于霍奇金淋巴瘤（三线）、肝细胞癌（二线）、非鳞状非小细胞肺癌（一线联合）、食管鳞癌（二线）。
⑶用于既往接受过二线及以上化疗后疾病进展或不可耐受的晚期鼻咽癌患者的治疗。
⑷联合顺铂和吉西他滨用于局部复发或转移性鼻咽癌患者的一线治疗。
- Associated Conditions
- -
- Associated Therapies
- -
First-line Treatment of Advanced/unresectable DDLPS
- Conditions
- Interventions
- First Posted Date
- 2024-11-19
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 49
- Registration Number
- NCT06694324
- Locations
- 🇨🇳
Fudan University, Cancer Hospital, Shanghai, Shanghai, China
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
- Conditions
- Interventions
- Drug: Albumin-Bound PaclitaxelDrug: OtherDrug: EpirubicinDrug: GemcitabineDrug: VinorelbineDrug: CisplatinDrug: IrinotecanDrug: FluorouracilDrug: NivolumabDrug: PembrolizumabDrug: DurvalumabDrug: AtezolizumabDrug: SintilimabDrug: TislelizumabDrug: CamrelizumabDrug: ToripalimabDrug: SerplulimabDrug: AdebrelimabDrug: EnvafolimabDrug: OsimertinibDrug: AlectinibDrug: VemurafenibDrug: PamiparibDrug: PyrotinibDrug: ImatinibDrug: PalbociclibDrug: SavolitinibDrug: Entrectinib
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Peking University Shenzhen Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT06692491
Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Ruijin Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT06693128
- Locations
- 🇨🇳
Sichuan Cancer Hospital & Institute, Chengdu, China
🇨🇳Changhai Hospital, Shanghai, China
🇨🇳Yantai Yuhuangding Hospital, Yantai, China
Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas
- Conditions
- Interventions
- First Posted Date
- 2024-10-23
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- West China Hospital
- Target Recruit Count
- 6
- Registration Number
- NCT06654297
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC
- Conditions
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2024-10-09
- Target Recruit Count
- 60
- Registration Number
- NCT06632405
A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation
- Conditions
- Interventions
- First Posted Date
- 2024-08-09
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Zhujiang Hospital
- Target Recruit Count
- 38
- Registration Number
- NCT06546280
- Locations
- 🇨🇳
Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
A Single Arm Clinical Study of Dendritic Cell Vaccine Loaded With Circular RNA Encoding Cryptic Peptide for Patients With HER2-negative Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-31
- Last Posted Date
- 2024-07-31
- Target Recruit Count
- 48
- Registration Number
- NCT06530082
SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC
- Conditions
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Huazhong University of Science and Technology
- Target Recruit Count
- 33
- Registration Number
- NCT06516445
- Locations
- 🇨🇳
Tongji hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab
- Conditions
- Interventions
- First Posted Date
- 2024-07-23
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 130
- Registration Number
- NCT06516289
- Locations
- 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China
A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-07-03
- Last Posted Date
- 2024-07-03
- Target Recruit Count
- 504
- Registration Number
- NCT06485271
- Locations
- 🇨🇳
Changzhi People's Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.